Terms: = Leukemia AND TCF7L2, ENSG00000148737, 6934, TCF-4 AND Treatment
10 results:
1. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
[TBL] [Abstract] [Full Text] [Related]
2. Mechanistic basis and efficacy of targeting the β-catenin-tcf7l2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Saenz DT; Fiskus W; Mill CP; Perera D; Manshouri T; Lara BH; Karkhanis V; Sharma S; Horrigan SK; Bose P; Kadia TM; Masarova L; DiNardo CD; Borthakur G; Khoury JD; Takahashi K; Bhaskara S; Lin CY; Green MR; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
Blood; 2020 Apr; 135(15):1255-1269. PubMed ID: 32068780
[TBL] [Abstract] [Full Text] [Related]
3. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
Saenz DT; Fiskus W; Manshouri T; Mill CP; Qian Y; Raina K; Rajapakshe K; Coarfa C; Soldi R; Bose P; Borthakur G; Kadia TM; Khoury JD; Masarova L; Nowak AJ; Sun B; Saenz DN; Kornblau SM; Horrigan S; Sharma S; Qiu P; Crews CM; Verstovsek S; Bhalla KN
Leukemia; 2019 Jun; 33(6):1373-1386. PubMed ID: 30575820
[TBL] [Abstract] [Full Text] [Related]
4. tcf7l2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway.
Zhao Q; Zhao S; Li J; Zhang H; Qian C; Wang H; Liu J; Zhao Y
Biomed Pharmacother; 2019 Jan; 109():1640-1649. PubMed ID: 30551418
[TBL] [Abstract] [Full Text] [Related]
5. β-catenin induces expression of prohibitin gene in acute leukemic cells.
Kim DM; Jang H; Shin MG; Kim JH; Shin SM; Min SH; Kim IC
Oncol Rep; 2017 Jun; 37(6):3201-3208. PubMed ID: 28440457
[TBL] [Abstract] [Full Text] [Related]
6. [Expression of ICAT and Wnt signaling-related proteins in the monocytic differentiation of HL-60 cells induced by a new steroidal drug NSC67657].
Wang JS; Wang WJ; Wang T; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):246-51. PubMed ID: 27087369
[TBL] [Abstract] [Full Text] [Related]
7. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells.
Fiskus W; Sharma S; Saha S; Shah B; Devaraj SG; Sun B; Horrigan S; Leveque C; Zu Y; Iyer S; Bhalla KN
Leukemia; 2015 Jun; 29(6):1267-78. PubMed ID: 25482131
[TBL] [Abstract] [Full Text] [Related]
8. CREBBP mutations in relapsed acute lymphoblastic leukaemia.
Mullighan CG; Zhang J; Kasper LH; Lerach S; Payne-Turner D; Phillips LA; Heatley SL; Holmfeldt L; Collins-Underwood JR; Ma J; Buetow KH; Pui CH; Baker SD; Brindle PK; Downing JR
Nature; 2011 Mar; 471(7337):235-9. PubMed ID: 21390130
[TBL] [Abstract] [Full Text] [Related]
9. JS-K, a nitric oxide-releasing prodrug, modulates ß-catenin/TCF signaling in leukemic Jurkat cells: evidence of an S-nitrosylated mechanism.
Nath N; Chattopadhyay M; Pospishil L; Cieciura LZ; Goswami S; Kodela R; Saavedra JE; Keefer LK; Kashfi K
Biochem Pharmacol; 2010 Dec; 80(11):1641-9. PubMed ID: 20797387
[TBL] [Abstract] [Full Text] [Related]
10. Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the tcf-4 activity.
Yamakawa-Karakida N; Sugita K; Inukai T; Goi K; Nakamura M; Uno K; Sato H; Kagami K; Barker N; Nakazawa S
Cell Death Differ; 2002 May; 9(5):513-26. PubMed ID: 11973610
[TBL] [Abstract] [Full Text] [Related]
